IDEXX Laboratories, Inc. $IDXX Shares Sold by Taylor Frigon Capital Management LLC

Taylor Frigon Capital Management LLC lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,692 shares of the company’s stock after selling 336 shares during the quarter. IDEXX Laboratories comprises about 1.3% of Taylor Frigon Capital Management LLC’s investment portfolio, making the stock its 25th biggest holding. Taylor Frigon Capital Management LLC’s holdings in IDEXX Laboratories were worth $2,517,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Opal Wealth Advisors LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at $29,000. MorganRosel Wealth Management LLC bought a new stake in IDEXX Laboratories in the first quarter worth about $26,000. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in IDEXX Laboratories by 55.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after acquiring an additional 30 shares during the last quarter. WPG Advisers LLC bought a new position in shares of IDEXX Laboratories during the 1st quarter valued at about $37,000. Finally, Bank of Jackson Hole Trust boosted its position in shares of IDEXX Laboratories by 328.6% during the 1st quarter. Bank of Jackson Hole Trust now owns 90 shares of the company’s stock valued at $39,000 after purchasing an additional 69 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael Lane sold 8,411 shares of the business’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total value of $5,279,921.14. Following the transaction, the executive vice president owned 7,132 shares in the company, valued at $4,477,041.68. The trade was a 54.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Nimrata Hunt sold 1,200 shares of the company’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $656.53, for a total value of $787,836.00. Following the completion of the transaction, the executive vice president directly owned 16,807 shares in the company, valued at approximately $11,034,299.71. The trade was a 6.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 54,057 shares of company stock worth $34,293,468. 0.98% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on IDXX. Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Sunday. Jefferies Financial Group assumed coverage on IDEXX Laboratories in a report on Tuesday, July 1st. They issued a “buy” rating and a $625.00 target price on the stock. Leerink Partners boosted their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. BTIG Research increased their price target on IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. Finally, Morgan Stanley boosted their price objective on IDEXX Laboratories from $722.00 to $765.00 and gave the stock an “overweight” rating in a report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $649.44.

IDEXX Laboratories Trading Up 2.3%

Shares of NASDAQ IDXX opened at $632.22 on Monday. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $688.12. The business has a 50-day moving average price of $625.60 and a two-hundred day moving average price of $529.00. The firm has a market capitalization of $50.58 billion, a PE ratio of 52.64, a PEG ratio of 4.09 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The firm’s revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.